Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815210) titled 'Phase I Trial of HHK101 in Patients With Schizophrenia' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Condition:
Schizophrenia
Intervention:
Drug: HHK101
Drug: HHK101
Drug: HHK101
Drug: HHK101
Drug: HHK101
Drug: HHK101
Drug: HHK101
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 30, 2026
Target Sample Size: 125
To know more, visit https://clinicaltrials.gov/study/N...